

## Special Issue

# State-of-the-Art and Perspectives in the Treatment of Hormone-Receptor-Positive Breast Cancer

### Message from the Guest Editor

Hormone-receptor-positive and HER2-negative breast cancer is the most common type of breast cancer. Endocrine therapy is the mainstay of treatment, and many patients do not need any other treatment. In both advanced and early cancer, additional therapies aiming at overcoming resistance have been developed. The emergence of novel targeted therapy in combination with endocrine therapy has shown improvement in outcomes, and may even make cytotoxic chemotherapy unnecessary in more patients in the future. In particular, CDK4/6 inhibitors and novel SERDs are promising options for the future. In this Special Issue of *Cancers*, we welcome original research and comprehensive review articles focusing on recent developments in the treatment of hormone-receptor-positive breast cancer, including special topics such as premenopausal patients and neoadjuvant treatment approaches.

### Guest Editor

Prof. Dr. Michael Gnant

Breast Health Center, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria

### Deadline for manuscript submissions

closed (15 April 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/132841](https://mdpi.com/si/132841)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)